International Clinical Trial: A Phase 1, Single-arm, Single-center, Open-label, Prospective Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120135) titled 'A Phase 1, Single-arm, Single-center, Open-label, Prospective Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer' on March 10.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Second University Hospital, Sichuan University

Condition: Ovarian cancer

Intervention: Dose Escalation:Three dose cohorts (3.33, 8.33, and 16.67 µg/kg), administered intraperitoneally BIW in a 2-week treatment cycle, after DLT observation, the investigator will assess whether to enter the follow-up period or continue tr...